Nutrition exerts considerable effects on health, and dietary interventions are commonly used to treat diseases of metabolic aetiology. Although cancer has a substantial metabolic component 1 , the principles that define whether nutrition may be used to influence outcomes of cancer are unclear 2 . Nevertheless, it is established that targeting metabolic pathways with pharmacological agents or radiation can sometimes lead to controlled therapeutic outcomes. By contrast, whether specific dietary interventions can influence the metabolic pathways that are targeted in standard cancer therapies is not known. Here we show that dietary restriction of the essential amino acid methionine-the reduction of which has anti-ageing and anti-obesogenic properties-influences cancer outcome, through controlled and reproducible changes to one-carbon metabolism. This pathway metabolizes methionine and is the target of a variety of cancer interventions that involve chemotherapy and radiation.
mice. n = 5 mice per group. MR, methionine restriction. b, Ninety sets of metabolic profiles from a were computed for singular values via singular value decomposition. Insert, two-sided t-test P values assessing the difference between control and methionine restriction in the first three modes. For definitions of the modes, see ' Analysis of the time-course metabolomics data' in Methods. n = 5 mice per group. Box limits are the 25th and 75th percentiles, centre lines are median, and the whiskers are the minimal and maximal values. c, Contribution of modes 2 and 3 in b ranked across all measured metabolites. d, Relative intensity of methionine and methionine sulfoxide. Mean ± s.d., n = 5 mice per group, *P < 0.05 by two-tailed Student's t-test. e, Schematic of experimental design using colorectal PDXs. Treatment, n = 7 mice per group (4 female and 3 male). Prevention, n = 8 mice per group (4 female and 4 male). P1, passage 1; P2, passage 2; P3, passage 3; P4, passage 4. f, Tumour growth curve and images of tumours at the end point from e. Mean ± s.e.m., *P < 0.05 by two-tailed Student's t-test.
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Nutrient composition in growth media has marked effects on cancer cell metabolism [3] [4] [5] . However, the extent to which diet-through its influence on levels of circulating metabolites (which is the in vivo equivalent of medium nutrient composition)-alters metabolic pathways in tumours and affects therapeutic outcomes is largely unknown. Previous studies have shown that the dietary removal of serine and glycine can modulate cancer outcome [6] [7] [8] . The availability of histidine and asparagine mediates the response to methotrexate 9 and the progression of breast cancer metastasis 10 , respectively. Whether such interventions broadly affect metabolism or have targeted effects on specific pathways related to these nutrients is unknown. One possibility for a specific dietary intervention in cancer is the restriction of methionine, which is an essential amino acid in one-carbon metabolism. Methionine is the most variable metabolite found in human plasma 11 , and has a myriad of functions as a result of its location in one-carbon metabolism 12 . Dietary restriction of methionine is known to extend lifespan 13, 14 and improve metabolic health [15] [16] [17] . One-carbon metabolism, through its essential role in redox and nucleotide metabolism, is the target of frontline cancer chemotherapies such as 5-fluorouracil (5-FU), and radiation therapy [18] [19] [20] . Indeed, some cancer cell lines are auxotrophic for methionine 21 , and depleting or restricting methionine from the diet may have anti-cancer effects in mice [22] [23] [24] . We therefore reasoned that methionine restriction could have broad anti-cancer properties by targeting a focused area of metabolism, and that these anti-cancer effects would interact with the response to other therapies that also affect one-carbon metabolism.
Methionine restriction alters metabolism in mouse liver and plasma after a long-term intervention 11 , but its effect on acute time scales has not been explored in as much detail. We switched the diet of C57BL/6J male mice from chow to a control (0.86% methionine, w/w) or a methionine-restricted (0.12% methionine, w/w) diet, and obtained plasma metabolite profiles over time (Fig. 1a) . We studied the metabolic dynamics using singular value decomposition (Fig. 1b, Extended Data  Fig. 1a ) and observed coordinated changes related to methionine and sulfur metabolism (Fig. 1b, c) , which were confirmed with hierarchical clustering (Extended Data Fig. 1b) . Methionine restriction reduced the levels of methionine-related metabolites within two days, and these levels were sustained throughout the intervention (Fig. 1d , Extended Table 1 ). Given these rapid and specific effects, we sought to evaluate methionine restriction in a series of pre-clinical settings that relate to one-carbon metabolism. We first considered two patient-derived xenograft (PDX) models of RAS-driven colorectal cancer, one of which (named CRC119) bears a KRAS(G12A) mutation and the other (named CRC240) a NRAS(Q61K) mutation (Extended Data Fig. 2a ). Mice were subjected to the control or methionine-restricted diet when the tumour was palpable (for treatment settings) or two weeks before inoculation (for prevention settings) (Fig. 1e) . Methionine restriction inhibited tumour growth in CRC119 (P = 5.71 × 10 −12 at the end point, two-tailed Student's t-test), and showed an inhibitory effect in CRC240 (P = 0.054 at the end point, two-tailed Student's t-test) (Fig. 1f) . Similar or higher amounts of food intake were observed with the methionine-restricted diet relative to the control diet (Extended Data Fig. 2b ), which implies the inhibitory effect was not due to caloric restriction. To gain insights into metabolism, we profiled metabolites in tumour, plasma and liver and found that in each case methionine restriction altered methionine and sulfur-related metabolism (Extended Data Fig. 2c-e) . A comparative metabolomics analysis across tissues showed that these effects most probably occur in a cell-autonomous manner (Extended Data Fig. 3, Methods) , and could be confirmed with data in cell culture (Extended Data Fig. 4) . Thus, the inhibition of tumour growth is at least partially (if not largely) attributable to lower circulating levels of methionine, which lead to cell-autonomous effects on tumours.
5-FU targets thymidylate synthase 18 and is a frontline chemotherapy for colorectal cancer, with therapeutic strategies achieving modest (approximately 60-65%) responses 25, 26 . We therefore tested whether methionine restriction could synergize with 5-FU in the CRC119 model (Fig. 2a) . We delivered a tolerable low dose of 5-FU that alone showed no effect on tumour growth (Fig. 2b) . Methionine restriction synergized with 5-FU treatment, leading to a marked inhibition of tumour growth, a broad effect on metabolic pathways in tumour, plasma and liver, and, most prominently, changes to nucleotide metabolism and redox state that were related to both the mechanistic action of 5-FU and methionine restriction (Fig. 2b-d, Extended Data Fig. 5a-g ). Fold changes of metabolites were highly correlated between plasma and liver (Spearman's rho = 0.38, P = 6.7 × 10 −11 ) but not between tumour and liver (Spearman's rho = 0.14, P = 0.02) or circulation (Spearman's rho = 0.14, P = 0.03), which indicates that methionine restriction exerted specific effects on tumours (Extended Data Fig. 5h ). Dietary restriction of methionine therefore synergizes with 5-FU, inhibiting the growth of colorectal cancer tumours and disrupting nucleotide metabolism and redox balance.
Next, we supplemented primary CRC119 cells and HCT116 colorectal cancer cells with nutrients related to methionine metabolism, in the presence of methionine restriction, 5-FU or both (Fig. 2e , Extended Data Fig. 6a, b) . Nucleosides and N-acetylcysteine (NAC), along with related supplements, partially alleviated the inhibition of cell proliferation due to methionine restriction, both with and without 5-FU treatment, in CRC119 cells (Fig. 2f ). These observations were largely replicated in HCT116 cells (Extended Data Fig. 6b ). Using serine uniformly labelled with 13 C (U-13 C-serine), we found that methionine restriction and 5-FU led to a further reduction of [M + 1] dTTP caused by 5-FU, with an increase of [M + 1] methionine (Fig. 2g , h, Extended Data Fig. 6c ). Thus, the synergistic effect between methionine restriction and 5-FU treatment is at least partially due to an increase in methionine synthesis, which competes with dTMP synthesis for the serine-derived one-carbon unit 5,10-methylene-tetrahydrofolate. These data support the conclusion that disruption to nucleotide metabolism and redox balance contributes to the inhibition of cell proliferation that is induced by methionine restriction.
To further explore the therapeutic potential of dietary restriction of methionine and related mechanisms, we considered an autochthonous mouse model of radiation resistance in soft-tissue sarcoma 27 . Extremity sarcomas were induced in FSF-Kras G12D/+ ;Trp53
FRT/FRT mice within two to three months of intramuscular delivery of adenovirus that expresses FlpO recombinase (Fig. 3a , Methods). The autochthonous and PDX models together span the spectrum of acceptable pre-clinical tumour models, and these cancer types allow for the investigation of treatments related to one-carbon metabolism (that is, chemotherapy in colorectal cancer and radiation in sarcoma). Methionine restriction alone did not alter tumour growth in this aggressive autochthonous model, and led to minimal effects on methionine metabolism ( (Fig. 3c) , which is comparable to effects seen with known radiosensitizing agents 28 . These effects appeared to be tumour-cell-autonomous and not attributable to protein synthesis or methylation reactions (Extended Data Fig. 7c-e) . Nevertheless, disruptions to nucleotide-and redox-related metabolism 
it r a t e P y r u v a t e L a c t a t e P y r u v a t e / la c t a t e , n = 7 mice per group, except for methionine restriction (n = 6). *P < 0.05 compared to the control group by two-tailed Student's t-test.
were observed and may underlie the effects of methionine restriction in combination with radiation ( Fig. 3d , e, Extended Data Fig. 7c-g ).
Finally, in a proof-of-principle clinical study, we recruited six healthy middle-aged individuals and subjected them to a low methionine diet (about 2.92 mg kg
)-equivalent to an 83% reduction in daily methionine intake-for three weeks (Fig. 4a, Methods) . Methionine restriction reproducibly suppressed methionine levels and altered circulating metabolism, with cysteine and methionine metabolism among the top altered metabolic pathways (Fig. 4b, Extended Data  Fig. 8a-c) . Methionine restriction reduced NAC and glutathione in all subjects, and affected metabolites related to methylation, nucleotide metabolism, the tricarboxylic acid cycle and amino acid metabolism (Fig. 4b, c, Extended Data Fig. 8d ). Plasma methionine-related metabolites in healthy humans were highly correlated with those in all mouse models (Spearman's rho = 0.53-0.73) (Extended Data Fig. 9a,  b, Fig. 4d ), which indicates that the response to methionine restriction is conserved between humans and mice. This controlled clinical study extends observations obtained from studies using methionine-free diets that are toxic 29, 30 to methionine restriction at levels that are tolerated in humans, and provide reasonable dietary possibilities-including levels of methionine that may be possible to obtain with vegan or some Mediterranean diets.
Together, we provide evidence that dietary restriction of methionine induces rapid and specific metabolic profiles in mice and humans that can be induced in a clinical setting. By disrupting the flux backbone of one-carbon metabolism with methionine restriction, vulnerabilities involving redox and nucleotide metabolism are created and can be exploited by administration of other therapies (here, radiation and antimetabolite chemotherapy) that target these aspects of cancer metabolism (Fig. 4e) . Thus, a synthetic lethal interaction is defined with the diet and the otherwise-resistant treatment modality. This study may help to further establish principles of how dietary interventions may be used to influence cancer outcomes in broader contexts.
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Methods
No statistical methods were used to predetermine sample size. Animals, diets and tissue collection. All animal procedures and studies were approved by the Institutional Animal Care and Use Committee (IACUC) at Duke University. All experiments were performed in accordance with relevant guidelines and regulations. All mice were housed at 20 ± 2 °C with 50 ± 10% relative humidity and a standard 12-h dark-12-h light cycle. The special diets with defined methionine levels that have previously been used 11, 16 were purchased from Research Diets; the control diet contained 0.86% methionine (w/w, catalogue no. A11051302) and methionine-restricted diet contained 0.12% methionine (w/w, catalogue no. A11051301). Three mouse models were used, and are described in 'PDX models of colorectal cancer' and ' Autochthonous soft-tissue sarcomas' . For all animal studies, mice were randomized to the control or methionine-restricted diet, and investigators were not blinded to allocation during experiments or outcome assessment. Methionine-restriction time-course study in healthy mice. Twelve-week-old male C57BL/6J mice (Jackson Laboratories) were subjected to either the control or the methionine-restricted diet ad libitum for three weeks. Mouse blood was sampled through tail bleeding in the morning (10:00-12:00) at days 1, 2, 4, 7, 10, 14, 17 and 21 after the dietary treatments. By day 21, all mice were euthanized for tissue collection. PDX models of colorectal cancer. PDX models of colorectal cancer with liver metastasis were developed as previously described 31, 32 , under an IRB-approved protocol (Pro00002435). In brief, CRC119 and CRC240 tumours were resected, washed and minced, and then passaged through JAX NOD.CB17-PrkdcSCID-J mice 2-5 times. For the dietary studies, CRC119 and CRC240 PDX tumours were minced in PBS at 150 mg/ml and 200 μl of tumour suspension was subcutaneously injected into the flanks of NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ mice from the Jackson Laboratory. Mice (four female and three or four male) were subjected to the control or methionine-restricted diet, either two weeks before the tumour injection or from when the tumour was palpable until the end point (a tumour volume of about 1,500 mm 3 ). Tumour size was monitored two to three times per week until the end point. For the combination therapy with the standard chemotherapy drug 5-FU, mice were subjected to the control or the methionine-restricted diet from two weeks before the tumour injection until the end point. When tumours were palpable, mice (four female and four male) were randomized to treatment of 5-FU (NDC 63323-117-10, 12.5 mg/kg three times per week) or vehicle (saline) through intraperitoneal injection. To minimize toxicity, we delivered an established low dose of 5-FU 33 . Tumour size was monitored two to three times per week until the end point. Autochthonous soft-tissue sarcomas. Primary soft-tissue sarcomas were generated as previously described 27, 34 . In brief, Trp53 FRT mice were crossed with mice that carry an Flp-activated allele of oncogenic Kras (FSF-Kras
G12D
) to generate FSFKras
G12D/+ ;Trp53
FRT/FRT compound conditional-mutant mice (KP mice). Trp53 FRT mice and FSF-Kras G12D mice were maintained on mixed C57BL/6J × 129SvJ backgrounds. Soft-tissue sarcomas were induced by intramuscular injection of an adenovirus that expresses FlpO into KP mice. Twenty-five microlitres of Ad5CMVFlpO (6 × 10 10 plaque-forming units per millilitre) was incubated with 600 μl minimum essential medium (Sigma-Aldrich) and 3 μl 2 M CaCl 2 (SigmaAldrich) for 15 min to form calcium phosphate precipitates. Fifty microlitres of precipitated virus was injected intramuscularly per mouse to generate sarcomas. Soft-tissue sarcomas developed at the site of injection in the lower extremity as early as two months after injection. FSF-Kras G12D mice were provided by T. Jacks at MIT, and Trp53 FRT mice had previously been generated at Duke University 27, 34 . KP mice (of mixed sex) were subjected to a control or methionine-restricted diet when tumours were palpable (about 150 mm 3 ), until the end point when the tumour tripled in size. Tumour size was monitored two or three times per week. For combination therapy with radiation, KP mice with palpable tumours were subjected to a single dose of 20 Gy focal radiation, which is moderately effective in this model 35 , using the X-RAD 225Cx small-animal image-guided irradiator (Precision X-Ray). The irradiation field was centred on the target via fluoroscopy with 40-kilovolt peak (kVp), 2.5-mA X-rays using a 2-mm aluminium filter. Sarcomas were irradiated with parallel-opposed anterior and posterior fields with an average dose rate of 300 cGy/min prescribed to midplane with 225-kVp, 13-mA X-rays using a 0.3-mm copper filter and a collimator with a 40 × 40-mm 2 radiation field at the treatment isocentre. The dose rate was monitored in an ion chamber by members of the Radiation Safety Division at Duke University. After radiation, mice were immediately subjected to the control or the methionine-restricted diet until the end point at which the tumour tripled in size. Tissues (tumour, liver and plasma) were collected at the time of tumour tripling. For metabolomics analysis, another cohort of mice on the combination therapy with radiation was euthanized at ten days after the radiation and dietary treatment (the average time point at which the tumour size tripled in the KP mice on the control or the methioninerestricted diet alone).
Tissue collection. For tissue collection from all the above mouse studies, mice were fasted in the morning for four hours (9:00-13:00). Tumour, plasma and liver were collected and then immediately snap-frozen, and stored at −80 °C until processed. Colorectal cancer cell lines. Early-passage primary CRC119 and CRC240 colorectal cancer cell lines were developed from the PDXs. PDXs were collected and homogenized, and the homogenates were grown in RPMI 1640 medium with addition of 10% fetal calf serum, 100,000 U/l penicillin and 100 mg/l streptomycin at 5% CO 2 . A single-cell clone was isolated using an O ring. The HCT116 cell line was a gift from the laboratory of L. Cantley, and was maintained in RPMI 1640 supplemented with 10% fetal bovine serum and 100,000 U/l penicillin and 100 mg/l streptomycin. Cells were grown at 37 °C with 5% CO 2 . Cell lines were authenticated and tested for mycoplasma at the Duke University DNA Analysis Facility by analysing DNA samples from each cell lines for polymorphic short tandem repeat markers using the GenePrint 10 kit from Promega. All cell lines were negative for mycoplasma contamination. Cell viability assay. Cell viability was determined by MTT (Invitrogen) assays. In brief, cells cultured in 96-well plates were incubated in RPMI medium containing MTT (final concentration 0.5 mg/ml) in a cell incubator for 2-4 h. The medium was then removed and replaced with 100 μl DMSO, followed by additional 10 min of incubation at 37 °C. The absorbance at 540 nm was read using a plate reader. For the metabolite rescue studies, 10 μM methionine (one tenth of the amount in the RPMI medium) was used to approximately model dietary methionine restriction. We evaluated the effects of supplementation of a suite of nutrients related to methionine metabolism, and the observed differences in metabolite profiles of the mouse models of colorectal cancer-including the one-carbon donors choline and formate; the sulfur donor homocysteine, with or without cofactor vitamin B12; nucleosides; and the antioxidant NAC-on methionine restriction alone or in combination with 5-FU treatment caused defects in cell proliferation. The following final conditions of metabolites were used: homocysteine (400 μM), vitamin B12 (20 μM), nucleosides (Millipore, 1×), choline (1 mM), formate (0.5 mM), NAC (1 mM) and 5-FU (2.5 μM). Human dietary study. The controlled feeding study was conducted at Penn State University Clinical Research Center and approved by the IRB of the Penn State College of Medicine, in accordance with the Helsinki Declaration of 1975 as revised in 1983 (IRB no. 32378). We have complied with all relevant ethical regulations. Healthy adults of mixed gender were recruited by fliers and word of mouth andas assessed for initial eligibility by telephone interview-were free of disease and not currently taking specific medications (including anti-inflammatory drugs, corticosteroids, statins, thyroid drugs and oral contraceptives). Final eligibility was assessed by standard clinical chemistry and haematology analyses. Written consent was obtained from eligible subjects and baseline resting metabolic rate was assessed by indirect calorimetry (Parvo Medics), physical activity by questionnaire and dietary intake by 3 unannounced 24-h diet recalls conducted by telephone in the week before returning to the clinic. All of the subjects-6 healthy adults (5 women and 1 man) with a mean ± s.d. age of 52.2 ± 3.19 years (range of 49-58 years) and body mass index of 27.6 ± 4.32 kg/m 2 -were placed on an methionine-restricted diet for the final 3 weeks, which provided 50-53% of energy from carbohydrate, 35-38% from fat and 12-13% from protein; total calories were adjusted individually on the basis of the baseline of resting metabolic rate and physical activity (calculated by the Harris Benedict Equation). Of the total protein, 75% was provided by a methionine-free medicinal beverage (Hominex-2, Abbott Nutrition) and the remaining 25% was from low-methionine foods such as fruits, vegetables and refined grains. The total methionine intake was about 2.92 mg kg
, which represented an 83% reduction in methionine intake compared to pre-test values from diet recalls (about 17.2 mg kg −1 day −1 at baseline level). The five-day-cycle menu was created and evaluated for nutrient content using the Nutrition Data System for Research. Blood was sampled by a registered nurse into EDTA tubes in the morning after overnight fasting, at the beginning and end of the diet period. Plasma was obtained after centrifugation at 5,000 r.p.m. for 10 min at 4 °C. All six subjects agreed to have their samples and data used for future research. Biosamples were anonymized by re-coding. There was no registration or pre-registration of this study. Metabolite profiling and isotope tracing. PDX primary cell lines were seeded in 6-well plates at a density of 2.0 × 10 5 cells per well. For overall polar metabolite profile, after overnight incubation cells were washed once with PBS and cultured for an additional 24 h with 2 ml of conditional RPMI medium containing 0 μM or 100 μM methionine plus 10% FBS. Cellular metabolites were extracted after incubation. For U-13 C-serine isotope tracing, both primary CRC119 cells and HCT116 cells were seeded in 6-well plates at a density of 2.0 × 10 5 cells per well. Cells were washed once with PBS after overnight incubation, and cultured for an additional 24 h with 2 ml of conditional RPMI medium containing 0 μM or 100 μM methionine with or without addition of 5-FU (3.4 or 10 μM) plus 10% FBS. Then, medium was replaced with fresh conditional RPMI medium (0 μM or 100 μM methionine) with or without addition of 5-FU (3.4 or 10 μM) containing tracer U-13 C-serine plus Letter reSeArCH 10% dialysed FBS. Cells were traced for 6 h, and tracing was followed by cellular metabolite extraction. Metabolite extraction. Polar metabolite extraction has previously been described 36 . In brief, tissue samples (liver and tumour) were pulverized in liquid nitrogen and then 3-10 mg of each was weighed out for metabolite extraction using ice-cold extraction solvent (80% methanol/water, 500 μl). Tissue was then homogenized with a homogenizer to an even suspension, and incubated on ice for an additional 10 min. The extract was centrifuged at 20,000g for 10 min at 4 °C. The supernatant was transferred to a new Eppendorf tube and dried in vacuum concentrator. For serum or medium, 20 μl of sample was added to 80 μl ice-cold water in an Eppendorf tube on ice, followed by the addition of 400 μl ice-cold methanol. Samples were vortexed at the highest speed for 1 min before centrifugation at 20,000g for 10 min at 4 °C. For cells cultured in 6-well plates, cells were placed on top of dry ice right after medium removal. One millilitre ice-cold extraction solvent (80% methanol/water) was added to each well and the extraction plate was quenched at −80 °C for 10 min. Cells were then scraped off the plate into an Eppendorf tube. Samples were vortexed and centrifuged at 20,000g for 10 min at 4 °C. The supernatant was transferred to a new Eppendorf tube and dried in vacuum concentrator. The dry pellets were stored at −80 °C for liquid chromatography with high-resolution mass spectrometry analysis. Samples were reconstituted into 30-60 μl sample solvent (water:methanol:acetonitrile, 2:1:1, v/v/v) and were centrifuged at 20,000g at 4 °C for 3 min. The supernatant was transferred to liquid chromatography vials. The injection volume was 3 μl for hydrophilic interaction liquid chromatography (HILIC), which is equivalent to a metabolite extract of 160 μg tissue injected on the column. High-performance liquid chromatography. An Ultimate 3000 UHPLC (Dionex) was coupled to Q Exactive-Mass spectrometer (QE-MS, Thermo Scientific) for metabolite separation and detection. For additional polar metabolite analysis, a HILIC method was used, with an Xbridge amide column (100 × 2.1 mm internal diameter, 3.5 μm; Waters), for compound separation at room temperature. The mobile phase and gradient information has previously been described 37 .
Mass spectrometry and data analysis. The QE-MS was equipped with a HESI probe, and the relevant parameters were: heater temperature, 120 °C; sheath gas, 30; auxiliary gas, 10; sweep gas, 3; spray voltage, 3.6 kV for positive mode and 2.5 kV for negative mode. Capillary temperature was set at 320 °C, and the S-lens was 55. A full scan range was set at 60 to 900 (m/z) when coupled with the HILIC method, or 300 to 1,000 (m/z) when low-abundance metabolites needed to be measured. The resolution was set at 70,000 (at m/z 200). The maximum injection time was 200 ms. Automated gain control was targeted at 3 Å ~ 10 6 ions. Liquid chromatography-mass spectrometry peak extraction and integration were analysed with commercially available software Sieve 2.0 (Thermo Scientific). The integrated peak intensity was used for further data analysis. For tracing studies using U-13 C-serine, 13 C natural abundance was corrected as previously described 38 . Statistical analysis and bioinformatics. Pathway analysis of metabolites was carried out with software Metaboanalyst (http://www.metaboanalyst.ca/ MetaboAnalyst/) using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database (http://www.genome.jp/kegg/). All data are represented as mean ± s.d. or mean ± s.e.m. as indicated. P values were calculated by a twotailed Student's t test unless otherwise noted. Analysis of the time-course metabolomics data. We first constructed a combinational matrix that contained the raw ion intensities of plasma metabolites from C57BL/6J mice (both the control and the methioninerestriction groups). For each group, there were 9 time points and 5 replicates for each time point, which resulted in a 311 × 90 matrix. This matrix was then log-transformed and iteratively row-normalized and column-normalized until the mean values of all rows and columns converged to zero. Singular value decomposition 39 was applied on the processed matrix to identify dominating dynamic modes:
in which A is the processed metabolomics matrix, σ i is the ith singular value (ranked from maximal to minimal), and σv i i T is termed the ith mode. Elements of u i (that is, the ith column vector of U) are coefficients for the ith mode. Modes 2 and 3 were defined as responding modes, owing to the significant difference between control and methionine-restriction values in both modes. For the ith metabolite, the total contribution of modes 2 and 3 to its dynamics was evaluated by:
2 . Mode 1 reflected an overall metabolic change due to switching diets at time zero. Modes 2 and 3 predominantly contained metabolites related to methionine and sulfur metabolism. Time-course metabolomics data of 50 metabolites with highest contribution of modes 2 and 3 were then clustered using the clustergram() function in MATLAB R2018b. All methods used were implemented in MATLAB code. Hierarchical clustering confirmed that a set of methionine-related metabolites was most rapidly suppressed, with other compensatory pathways changing at later times. Cross-tissue comparison of metabolite fold changes in PDX and sarcoma models. Spearman's rank correlation coefficients were computed on metabolites measured in plasma, tumour and liver. The distance between fold changes in tissues A and B (for example, liver and tumour) was computed by measuring the Euclidean distance between the two vectors of the fold changes that contained all metabolites measured in both A and B. Multidimensional scaling was then applied to visualize the tissues in two dimensions; a stress function, which measures the difference between the dimension-reduced values and the values in the original dataset, was minimized:
in which N is the total number of metabolites used in the original dataset, d i,j is the Euclidean distance between the ith and jth data points in the original dataset, and x i is the ith point in the dimension-reduced dataset. All methods used here were implemented in MATLAB.
Methionine-related and methionine-unrelated metabolites. To determine whether the effect of methionine restriction on tumour growth is systemic, cell autonomous or both, we conducted an integrated analysis of global changes in the metabolic network across tumour, plasma and liver within each model from the prevention study in PDX models of colorectal cancer in Fig. 1f . Methionine-related and -unrelated metabolites were defined according to their distance to methionine in the genome-scale metabolic human model Recon 2 (ref.
40
). Metabolites were defined as methionine-related if the distance to methionine was less than or equal to four, or methionine-unrelated when the distance to methionine was larger than four. Metabolites were mapped by their KEGG identity between the metabolomics dataset and Recon 2. Quantification of methionine concentrations. To quantify methionine concentrations in plasma, liver and tumour across the mouse models and in healthy humans, two additional datasets of metabolomics profiles in human plasma with their corresponding absolute methionine concentrations (quantified using 13 C-labelled standards) were used. The raw intensities across all samples were log-transformed and normalized. Linear regression was then performed on the normalized datasets to predict absolute methionine concentrations. Four normalization algorithms including cyclic loess, quantile, median and z-score were tested. Among the normalization algorithms, cyclic loess had the highest R 2 statistics in the corresponding linear regression model (R 2 = 0.74 for cyclic loess compared to 0.66 for quantile, 0.68 for median and 0.70 for z-score). Thus, the cyclic-loess-normalized dataset was used for the final model training, which generated the following equation describing the model: log(methionine concentration) = 1.001676 log(I methionine ) − 14.446017. In this equation, methionine concentration refers to the absolute methionine concentration, and I methionine is the cyclic-loess-normalized value of methionine intensity. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
The metabolomics data reported in this study have been deposited in Mendeley Data (https://doi.org/10.17632/zs269d9fvb.1).
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All computer code is available at: https://github.com/LocasaleLab/Dietary_methio-nine_restriction. 
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The following mouse strains were used in the manuscript: C57BL/6J mice: male, 12-week-old; NOD.CB17-PrkdcSCID-J mice: male and female, 8-10-week-old; NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice: male and female, 8-10-week-old; C57BL/6J × 129SvJ mice carrying p53FRT and FSF-KrasG12D: male and female, 6-10-week-old;
